Spots Global Cancer Trial Database for recurrent malignant glioma

Every month we try and update this database with for recurrent malignant glioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults	NCT04323046	Glioblastoma Malignant Gliom... Recurrent Gliob... Recurrent Malig... Recurrent Grade... Grade III Gliom...	Nivolumab Quality-of-Life... Questionnaire A...	6 Months - 25 Years	University of California, San Francisco
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	NCT03526250	Advanced Malign... Recurrent Child... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft...	Laboratory Biom... Palbociclib Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma	NCT05045027	Glioma Malignant Gliom... Recurrent Gliom... Recurrent Malig...	Biospecimen Col... Diagnostic Imag... Magnetic Resona...	18 Years -	Jonsson Comprehensive Cancer Center
Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma	NCT00501891	Glioblastoma Mu...	Bevacizumab Metronomic Temo...	18 Years -	Duke University
A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)	NCT05540873	Recurrent Malig...	YYB-103	19 Years - 74 Years	CellabMED
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme	NCT00076986	Glioblastoma Mu...	IL13-PE38QQR surgery and cat... prolifespan 20 ... surgery and waf...	18 Years -	INSYS Therapeutics Inc
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype	NCT02658279	Glioma Recurrent Malig...	Pembrolizumab	18 Years -	Memorial Sloan Kettering Cancer Center
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors	NCT03598244	Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim...	Biospecimen Col... Magnetic Resona... Savolitinib X-Ray Imaging	6 Years - 21 Years	National Cancer Institute (NCI)
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04284774	Malignant Solid... Recurrent Adren... Recurrent Ectom... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Melan... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Recurrent WHO G... Refractory Adre... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Mela... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory WHO ...	Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Tipifarnib	12 Months - 21 Years	National Cancer Institute (NCI)
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma	NCT00613054	Glioblastoma Gliosarcoma	Zactima, Gleeve...	18 Years -	Duke University
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme	NCT00076986	Glioblastoma Mu...	IL13-PE38QQR surgery and cat... prolifespan 20 ... surgery and waf...	18 Years -	INSYS Therapeutics Inc
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04320888	Hematopoietic a... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Lymph... Recurrent Malig... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent WHO G... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Lymp... Refractory Mali... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory WHO ... Wilms Tumor	Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Selpercatinib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma	NCT02208362	Recurrent Gliob... Recurrent Malig... Recurrent WHO G... Recurrent WHO G... Refractory Glio... Refractory Mali... Refractory WHO ... Refractory WHO ...	IL13Ralpha2-spe... IL13Ralpha2-spe... Laboratory Biom... Magnetic Resona... Magnetic Resona... Quality-of-Life...	12 Years - 75 Years	City of Hope Medical Center
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas	NCT02192359	Recurrent Anapl... Recurrent Anapl... Recurrent Anapl... Recurrent Gliob... Recurrent Glios... Recurrent Malig... Recurrent WHO G...	Carboxylesteras... Irinotecan Irinotecan Hydr... Laboratory Biom... Pharmacological...	18 Years - 69 Years	City of Hope Medical Center
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)	NCT06193174	Recurrent Malig... Glioblastoma Mu... Gliosarcoma of ... Anaplastic Astr...	C134 Re-Adminis...	18 Years -	University of Alabama at Birmingham
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma	NCT00734864	Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Glioma	enzyme-inducing... enzyme-inducing...	18 Years -	Duke University
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma	NCT00734864	Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Glioma	enzyme-inducing... enzyme-inducing...	18 Years -	Duke University
D2C7 for Adult Patients With Recurrent Malignant Glioma	NCT02303678	Malignant Gliom... Brain Tumor, Re...	D2C7-IT	18 Years -	Duke University
Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas	NCT05139056	Recurrent Anapl... Recurrent Anapl... Recurrent Anapl... Recurrent Gliob... Recurrent Glios... Recurrent Malig... Recurrent WHO G... Recurrent WHO G...	Neural Stem Cel... Resection	18 Years -	City of Hope Medical Center
Ph I SU011248 + Irinotecan in Treatment of Pts w MG	NCT00611728	Glioblastoma	SU011248 & Irin...	18 Years -	Duke University
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors	NCT03598244	Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim...	Biospecimen Col... Magnetic Resona... Savolitinib X-Ray Imaging	6 Years - 21 Years	National Cancer Institute (NCI)
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma	NCT00613054	Glioblastoma Gliosarcoma	Zactima, Gleeve...	18 Years -	Duke University
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors	NCT05278208	High Grade Glio... Meningioma Embryonal Tumor Medulloblastoma Anaplastic Epen... Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim...	LUTATHERA® (Lut...	4 Years -	Nationwide Children's Hospital
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma	NCT04388475	Recurrent Malig... Brain Glioblast...	OKN-007 Temozolomide (T...	18 Years -	Oblato, Inc.
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma	NCT00734864	Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Glioma	enzyme-inducing... enzyme-inducing...	18 Years -	Duke University
Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma	NCT00611325	Glioblastoma Gliosarcoma	Avastin Bortezomib	18 Years -	Duke University
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	NCT03526250	Advanced Malign... Recurrent Child... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft...	Laboratory Biom... Palbociclib Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: